Investors look to trade sales for European life science firms, says Ruston Poole survey
This article was originally published in Scrip
Executive Summary
European investors in life science companies believe that it will be at least two years before the IPO market opens up, but thereafter IPOs will again provide a good exit route for early-stage companies.